Cytek Biosciences Reports Significant Net Loss Increase and Sharp EBITDA Decline for FY2025 Amidst Modest 2026 Outlook

summarizeSummary

Cytek Biosciences reported a significant increase in its full-year 2025 net loss to $66.5 million and a sharp decline in Adjusted EBITDA, largely due to a deferred tax asset valuation allowance, despite some Q4 revenue acceleration and modest 2026 guidance.

check_boxKey Events

• Significant Increase in Net Loss

  The company reported a full-year 2025 net loss of $66.5 million, a substantial increase from a net loss of $6.0 million in 2024.

• Sharp Decline in Adjusted EBITDA

  Adjusted EBITDA for full-year 2025 fell significantly to $5.0 million, down from $22.4 million in 2024.

• Deferred Tax Asset Valuation Allowance

  A non-cash valuation allowance of $33.1 million was recorded against deferred tax assets for the full year, reflecting uncertainty regarding the realization of future tax benefits.

• Modest Full-Year Revenue Growth with Q4 Acceleration

  Full-year 2025 revenue increased by 1% to $201.5 million, with fourth-quarter 2025 revenue growing 8% to $62.1 million, marking the highest quarterly revenue historically.

auto_awesomeAnalysis

Cytek Biosciences reported a substantial increase in its full-year 2025 net loss, primarily driven by a significant non-cash valuation allowance against deferred tax assets and a sharp decline in Adjusted EBITDA. This financial deterioration, despite some fourth-quarter revenue acceleration and modest 2026 revenue guidance, indicates significant operational challenges. The deferred tax asset valuation allowance reflects management's uncertainty about future taxable income, which is a strong negative signal. Investors will likely scrutinize the company's ability to improve operational efficiency and return to profitability in the coming year.